George Kollias: Brief CV
| George Kollias, Ph.D. Acting Director of the Institute of Immunology, Biomedical Sciences Research Center ‘Alexander Fleming’, Vari / Athens, Greece. |
|
Dr. George Kollias,
born in 1958, received his B.Sc. in Biology from the University of
Athens, Greece and Ph.D. training from 1980 to 1984 in Molecular Biology
at the National Hellenic Research Foundation. He has post-doctoral
experience in the field of gene structure and expression (Laboratory of
Gene Structure and Expression, National Institute for Medical Research,
Mill Hill, London, UK) and from 1990-2000 he established the Laboratory
of Molecular Genetics at the Hellenic Pasteur Institute in Athens,
Greece. From 2000-2002, he was appointed Director of the Institute for
Immunology at the
Biomedical Sciences Research Center "Alexander
Fleming", and from 2002-2010 he has served as the Center's President
and Scientific Director. He is currently Acting Director of the
George Kollias has a sound expertise in
transgenic, gene mutational and knockout technology, molecular and
cellular biology and immunology and is a leader in the field of TNF
function in pathophysiology. His research is highly cited for
establishing and characterizing disease pathways in animal models of
chronic inflammation and autoimmunity (e.g. Rheumatoid Arthritis,
Inflammatory Bowel Disease, Multiple Sclerosis, endotoxic shock and
systemic lupus).
Dr Kollias is placed amongst the
top cited European scientists in Rheumatology
research for the period 1997-2008. He has published over 145 primary
research articles in peer-reviewed journals and more than 35 reviews and
commentaries. His work has received over
15.000 citations and an h-index of 59 (data from
Researcher ID)
His laboratory is supported by
several competitive grants from European
Commission and National sources as well as by the international
biopharmaceutical industry. From 2005 - 2009 Dr. Kollias coordinated a
consortium of 24 EU organizations constituting the FP6 Network of
Excellence
MUGEN ("Functional Genomics in mutant mouse models as tools to
investigate the complexity of human immunological disease", 11M€). He is
currently a core member of the Innovative Medicines Initiative (IMI) project
BeTheCure (Total budget: 38 Mi€, 2011-2016).
In 2005 he founded the first CRO-biotech spin-off of BSRC Fleming,
Biomedcode Hellas SA.
Since 2000, Dr. Kollias is an elected member of the European Molecular
Biology Organization (EMBO). He serves as an advisor for scientific
organizations and consults for industry. Dr. Kollias also serves as
invited speaker and chairman and as a member of the Organising and
Scientific Committees of several scientific meetings throughout the
world. Dr. Kollias has been a member of the National Council on Research
and Technology of the Ministry of Development (2001-2003 and 2005-2009)
and has served as an elected President of the Council of the Directors
of the Greek Research Centers (2009-2010). He is currently the National
Representative of
